31 Mar '22 18:17>1 edit
Ivermectin - everyone wanted more research. Here it is:
https://www.nejm.org/doi/full/10.1056/NEJMoa2115869
We conducted a double-blind, randomized, placebo-controlled, adaptive platform trial involving symptomatic SARS-CoV-2–positive adults recruited from 12 public health clinics... A total of 3515 patients were randomly assigned to receive ivermectin (679 patients), placebo (679), or another intervention (2157). Overall, 100 patients (14.7% ) in the ivermectin group had a primary-outcome event, as compared with 111 (16.3% ) in the placebo group (relative risk, 0.90; 95% Bayesian credible interval, 0.70 to 1.16).... There were no significant effects of ivermectin use on secondary outcomes or adverse events. Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among outpatients with an early diagnosis of Covid-19. (Funded by FastGrants and the Rainwater Charitable Foundation; TOGETHER ClinicalTrials.gov number, NCT04727424. opens in new tab.)
https://www.nejm.org/doi/full/10.1056/NEJMoa2115869